LifeSplice Pharma logo

LifeSplice Pharma LLC

Lifesplice Pharma LLC is an early stage biotech company developing long lasting RNA based drugs called splice modulating oligomers (SMOs) to treat several neurological disorders. Lifesplice Pharma was co-founded by Gordon J. Lutz, and Melanie Tallent, developed Splice Modulating Oligomers (SMOs) that directly modulate dysregulated pre-mRNA splicing and alternative splicing which are both frequently linked to severe neurological disorders. The program consists 2 preclinical stage small molecules against ALS and Epilepsy.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttp://lifesplicepharma.com
Disease Focus
STOCK CODENon Listed
Address
1 Great Valley Parkway Suite 20, 19355
Malvern
United States
Email
Contact Number
+1 610-296-5401

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/lifesplice-pharma” connections=”true” suffix=””]

LifeSplice was awarded more than $3.7 Mn NIH Phase 2 and 1 SBIR grant for IND-enabling GLP Saftey + CMC studies of our lead drug LSP-GR1 for treating ALS.